Our History

Alexion Timeline: A Commitment to Breakthrough Innovation

Since our founding in 1992, Alexion has given hope to people who had none and shined a light on those who felt isolated and alone. We have remained steadfast in our pursuit of groundbreaking innovation, and have delivered solutions to challenges that once seemed impossible. Here are some of the milestones throughout our history.

Company Milestone Product Milestone Awards and Recognition
  • 2018
    Alexion and Complement Pharma partner to co-develop pre-clinical complement inhibitor for neurodegenerative disorders
    Alexion acquires Wilson Therapeutics, strengthening its pipeline and expanding its focus on metabolic and neurologic disorders
    Forbes Logo
    Alexion is named one of the World's Most Innovative Companies by Forbes consecutively from 2012 to 2018
    Alexion’s data sciences work contributes to Rady Children’s Institute for Genomic Medicine scientists’ achievement of new GUINNESS WORLD RECORDS™ title for fastest genetic diagnosis
  • 2017
    Soliris® (eculizumab) is approved in the U.S. and Japan for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive and in the European Union for the treatment of refractory generalized myasthenia gravis (gMG) in adult patients who are anti-AchR antibody-positive.
  • 2016
    Kanuma® is approved as a treatment for patients with lysosomal acid lipase deficiency (LAL-D) in Japan
    Alexion receives 2016 Rare Impact Award from the National Organization for Rare Disorders (NORD) and is named as Industry Innovation Honoree for the Company’s work in bringing Strensiq® and Kanuma® to market
    Alexion receives orphan drug designation (ODD) for ALXN1007 for the treatment of graft-versus-host disease (GVHD) from the U.S. FDA and the European Commission (EC)
    Kanuma® receives 2016 German Prix Galien Award in the Orphan Product category
    Science names Alexion as a Top Employer in both 2015 and 2016
    Alexion initiates two Phase 3 clinical trials of ALXN1210 in complement inhibitor treatment-naïve patients with PNH and aHUS, and receives ODD for ALXN1210 for the treatment of patients with PNH from the EC
  • 2015
    Strensiq® (asfotase alfa) is approved as a treatment for patients with hypophosphatasia (HPP) in the U.S., EU, Japan and Canada
    Kanuma® (sebelipase alfa) is approved as a treatment for patients with lysosomal acid lipase deficiency (LAL-D) in the U.S. and EU
    Alexion is named one of Fortune Magazine’s Fastest Growing Companies in 2011, 2012, 2014 and 2015
  • 2014
    Soliris® receives orphan drug designation (ODD) for multiple potential indications:
    • Prevention of delayed graft function (DGF) in renal transplant patients from the FDA, and prevention of DGF after solid organ transplantation from the EMA
    • Treatment of refractory myasthenia gravis (MG) from the FDA and EMA
    Alexion initiates multinational registration trials of eculizumab as a potential treatment for patients with NMO, MG and DGF
    Connecticut Magazine names Alexion one of the top workplaces in the state in both 2010 and 2014
  • 2013
    Asfotase alfa receives Breakthrough Therapy Designation from the FDA for the treatment of HPP, and cPMP (ALXN1101) receives Breakthrough Therapy Designation for the treatment of molybdenum cofactor deficiency (MoCD) Type A
    Soliris® is approved as a treatment for patients with aHUS in Japan
    Soliris® receives orphan drug designation (ODD) for the treatment of neuromyelitis optica (NMO) from the FDA and EMA
  • 2012
    Alexion acquires asfotase alfa, the first potential treatment for patients with hypophosphatasia (HPP)
    New England Journal of Medicine publishes data from Phase 2 study of asfotase alfa in
    life-threatening HPP
    Alexion is added to the S&P 500 Index of leading global companies
    Alexion presented with the Partners in Progress Award from the National Organization for Rare Diseases (NORD)
  • 2011
    The FDA and the EMA approve Soliris® as the first and only treatment for adult and pediatric patients with aHUS
  • 2010
    U.S. Green Building Council (USGBC) twice recognizes Alexion with LEED Certification Awards for constructing, operating and maintaining interiors that meet the highest green building and performance standards
  • 2009
    Soliris® receives the Prix Galien France Award for Drugs for Rare Diseases
  • 2008
    Soliris® is first used as a treatment for patients with atypical hemolytic uremic syndrome (aHUS) in France and Germany
    Soliris® receives the Prix Galien USA Award for Best Biotechnology Product
  • 2007
    Soliris® (eculizumab) receives approval from the FDA and European Medicines Agency (EMA) as the first and only treatment for patients with PNH
    Alexion honored with the Corporate Leadership Award from the National Organization for Rare Disorders (NORD)
    Alexion earns the Award of Excellence from Connecticut United for Research Excellence (CURE)
  • 2005
    Second pivotal Phase 3 study of eculizumab in patients with PNH begins (SHEPHERD)
  • 2002-2004
    Pilot study with eculizumab commences in Leeds, England in paroxysmal nocturnal hemoglobinuria (PNH)
    New England Journal of Medicine publishes positive results from pilot study of eculizumab in 11 patients with PNH
    First pivotal Phase 3 study of eculizumab commences in patients with PNH (TRIUMPH)
  • 1996-1998
    First in-human clinical trial of eculizumab begins
  • 1992-1994
    C5 complement inhibitor development program commences